1 - Departamento de Pediatria, Hospital Dona Estefânia, ULS S José
2 - Unidade de Hematologia, Área de Pediatria, ULS S José
- Publicação Acta Med Port. 2024 Apr. 1;37(4):294-5
Resumo: Chronic immune thrombocytopenia (ITP) is often associated with limited activity and fear of bleeding which affect the patient’s quality of life. Eltrombopag is the only oral thrombopoietin receptor agonist approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in pediatric patients older than one year with chronic ITP refractory to other treatments. We conducted a single-center retrospective study between January 2018 and December 2022, with the aim of evaluating the efficacy of eltrombopag in patients with persistent and chronic ITP